Human bladder cancer (BCa) is one of the most commonly diagnosed malignancies worldwide. It has high recurrence rates and lowgrade malignancy, thus representing an important public health concern. An increasing number of studies suggest that longnoncoding RNAs (lncRNAs) play important roles in various biological processes and disease pathologies, including cancer.
Introduction
Human bladder cancer (BCa) is one of the most common malignancies worldwide, with high morbidity and mortality. [1] BCa encompasses a wide spectrum of disease, ranging from superficial, well-differentiated carcinomas that do not affect survival, to highly aggressive tumors with poor prognosis. [2, 3] In 2017, there were approximately 79,030 new cases diagnosed in the United States (60,490 males and 18,540 females), leading to 16,870 deaths (12,240 males and 4630 females). [4] Although BCa is linked to several universal genetic changes, identifying the mechanisms that underlie cancer progression remains challenging due to complicated disease processes and numerous molecular interactions. Therefore, the identification of potential biomarkers and novel targets for prognosis, diagnosis, and treatment is urgently needed.
Recently, the role that long-noncoding RNAs (lncRNAs) may play in cancer progression has received increased attention. These are nonprotein coding transcripts longer than 200 nucleotides [5] that are broadly distributed throughout the genome. [6] [7] [8] [9] Previous studies have demonstrated that lncRNAs are involved in modulating gene expression at the transcriptional, post-transcriptional, and epigenetic levels. [10] Evidence also suggests that lncRNAs contribute to the control of a variety of biological processes (BP), including the maintenance of genome integrity, stem cell pluripotency, cell differentiation, genomic imprinting, and X inactivation. [11] [12] [13] As such, lncRNAs are thought to associate with the pathogenesis of many different cancers, including hepatocellular liver cancer, [14] esophageal squamous cell carcinoma, [15] colorectal cancer, [16] renal cell carcinoma, [17] gastric cancer, [18] and prostate cancer. [19] These studies indicate that lncRNAs could potentially serve as diagnostic or prognostic markers for human cancer, including BCa. However, the exact functions of most lncRNAs, including any putative role in BCa, are unclear and further study is urgently required.
In order to better understand how noncoding RNAs (ncRNAs) may be involved in BP and pathogenesis, a competitive endogenous RNA (ceRNA) network hypothesis has been proposed. [20] This framework aims to describe how 3 types of RNA transcript (lncRNA, miRNA, and mRNA) interact to regulate transcription, creating a new fundamental "language" that describes transcriptional control by miRNA binding sites and miRNA response elements. A key hypothesis of ceRNA theory is that miRNAs play an important role in the ceRNA network by binding mRNA, inhibiting mRNA expression. LncRNAs also affect transcription by competing with miRNAs, subsequently affecting expression of the target mRNA. [21] Research has also shown that ceRNA and related theories may provide an important new tool to advance tumor diagnoses and treatment options. For example, Sumazin et al [22] systematically investigated an mRNA-related ceRNA network in glioblastoma cells, confirming that these ceRNA interactions mediate the crosstalk between oncogenic pathways. Aiding this research is several well-established RNA databases that provide useful information to understand ncRNA-mediated ceRNA regulatory mechanisms. These include the long-noncoding RNA-associated diseases (LncRNADisease) database, [23] the Human miRNA Disease Database, [24] and database of Differentially Expressed MiRNAs in human Cancers dbDEMC. [25] There are also several miRNA-target interactions databases, including miRcode [26] and miRanda, [27] [28] [29] and the ceRNA-specific long-noncoding competing endogenous database (lnCeDB). [30] To establish if lncRNAs have a role in the progression of BCa, our study constructed a global triple RNA network based on ceRNA theory using data from the Cancer Genome Atlas (TCGA). Gene ontology (GO) and pathway analyses were performed using the BinGO plug-in for Cytoscape and the Database for Annotation, Visualization, and Integration Discovery (DAVID), respectively, to reveal any associations between mRNAs in the network and BCa. Next, important hub lncRNAs were identified in the lncRNA-miRNA-mRNA network and new subnetworks formulated that centered on these lncRNAs. Further GO and pathway analysis of these subnetworks revealed several important processes and miRNAs that link these lncRNAs to BCa. These data provide valuable insights into the molecular progression of BCa and will contribute to identify potential mechanisms of pathogenesis. This will improve the diagnosis and prognosis of BCa, in addition to aiding the identification of putative drug targets.
Materials and methods

Data collection and preprocessing
A total of 418 patients with BCa were enrolled in our comprehensive integrated analysis. Data were downloaded from the TCGA database (http://tcga-data.nci.nih.gov/) using the Data Transfer Tool provided with GDC Apps. For the study, level 3 mRNASeq gene expression data, miRNASeq data, and clinical information of patients were downloaded (http://tcga-data.nci. nih.gov/). Sequencing data were collected using Illumina HiSeq RNASeq and Illumina HiSeq miRNASeq platforms (Illumina, San Diego, CA) and the study was performed in line with the publication guidelines provided by TCGA (http://cancergenome. nih.gov/publicaitons/publicationguidelines). Ethical approval was not necessary in our study because the expression profiles were downloaded from the public database and no new experiments in patients or animals were performed.
Screening of differentially expressed genes
EdgeR (http://bioconductor.org/packages/release/bioc/html/edg eR.html) [31] was used to screen differentially expressed lncRNAs (DElncRNAs), miRNAs (DEmiRNAs), and mRNAs (DEmRNAs) from the dataset by comparing normal and BCa groups. P values were calculated using post hoc tests using a significance threshold of P < .01 and jfold change (FC)j > 2.0. Hierarchical clustering was visualized using the gplots package of R (http:// cran.r-project.org/web/packages/gplots/index.html). [32] 
Competing endogenous RNA network analysis
To investigate the potential roles of lncRNAs within the mediated ceRNA network, a coexpression network of DEmRNAs, DElncRNAs, and DEmiRNAs was built using Cytoscape v 3.5.1 software. [33] miRNA-targeted mRNAs were retrieved from miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/). Each miRNA-mRNA pair used was preciously experimentally validated by reporter assay and at least 2 of the following methods; qRT-PCR, western blotting, microarray, and nextgeneration sequencing experiments in miRTarBase. In addition, lncRNA-miRNA interactions were constructed based on miRcode (http://www.microde.org/). [26] 
GO and pathway analysis
The GO analysis database (http://geneontology.org) was used to annotates genes and gene products to identify associating biological attributes in the transcriptome and high-throughput genome data. [34, 35] Similarly, the Kyoto Encyclopedia of Genes and Genomes (KEGG) knowledge database (http://www.kegg. jp/) was used for the systematic analysis of gene functions, linking genomic information with higher-order functional information. [36] To evaluate pathways and BP that were DE in the ceRNA network, the DAVID [37, 38] (http://david.abcc.ncifcrf.gov/) and the BinGO [39] plug-in for Cytoscape were used for functional enrichment analysis. KEGG pathways and GO BP were highlighted at a significance threshold of P < .05 [40] and a Àlog 10 (P) denoted enrichment scores with significant pathway correlations.
Construction of key lncRNA-miRNA-mRNA subnetworks
Each downloaded lncRNA, and its linked miRNAs and mRNAs in the ceRNA network, were extracted and used to construct new subnetworks using Cytoscape software. In the study, degree centrality (a fundamental parameter in network theory) was adopted to evaluate each node in order to identify key lncRNAs in the subnetwork. Degree centrality was defined as the number of adjacent links for the node and was determined from the number of interactions that connected each RNA to its neighbors. The degree centrality method was calculated using the CytoHubba [41] plug-in for Cytoscape. Further analysis involved identifying the GO and pathway annotations for each of the key lncRNAs by establishing their mRNA neighbors in the lncRNAmiRNA-mRNA subnetwork. GO interaction networks were then reconstructed using the BinGO plug-in for Cytoscape. 
Survival analysis
To identify any prognostic DEmRNA, DEmiRNA, or DElncRNA signatures, clinical data from patients with BCa were collected from the TCGA. Survival curves for each sample with DElncRNAs, DEmiRNAs, and DEmRNAs were creating using the "survival" R package. Univariate survival was estimated using a Kaplan-Meier univariate survival method.
[42] P < .01 was considered significant.
Results
Identifying DEmRNAs, DEmiRNAs, and DElncRNAs in BCa samples
The RNA expression profiles of patients with BCa and corresponding clinical information were downloaded from the TCGA database using the Data Transfer Tool. We then used EdgeR to identify significantly DEmRNAs, DEmiRNAs, and DElncRNAs between BCa and normal samples (DEmRNAs, DEmiRNAs, and DElncRNAs Fig. 1. 
Construction of the ceRNA network
To reveal how lncRNA may mediate transcription in BCa by affecting mRNA and miRNA binding, a ceRNA network based on the lists of DElncRNAs, DEmiRNAs, and DEmRNAs was constructed and visualized using Cytoscape software. As shown in Fig. 2 , the lncRNA-miRNA-mRNA network was comprised of 23 miRNA nodes, 52 mRNA nodes, 59 lncRNA nodes, and 365 edges. We found that most DEmRNAs were tumor-related genes and including CBX2, DUSP2, ELAVL2, HOXB5, and ZEB1. Gene information was retrieved from the Onco database (http://www.bushmanlab.org/links/genelist).
Predicated functions of mRNAs within the lncRNAmiRNA-mRNA network
To establish context of our ceRNA network, we inferred the roles of each lncRNA based on the functions of connected mRNAs. lncRNAs were typically central and connected to one or more mRNAs in the network. The results of an initial GO analysis revealed 300 enriched GO terms at the "Biological Process" level for mRNAs connected to lncRNAs in the network. These included various BP, such as negative regulation of cell migration, regulation of cellular metabolic process, and regulation of cell proliferation. In order to fully explore the inner relationships between these GO terms, a GO interaction network was constructed using the BinGO plug-in for Cytoscape (Fig. 3) . We next filtered GO terms with P < .05 and Benjamini corrected P < .05, leaving 122 that were determined to be significantly enriched. The 10 most significant BP are shown in Fig. 4A . Finally, KEGG pathway analysis revealed that 15 pathways were significantly enriched, particularly microRNAs involved in cancer, prostate cancer, and p53 signaling. The 10 most significant KEGG pathways are shown in Fig. 4B .
The construction of lncRNA-miRNA-mRNA subnetworks containing key lncRNAs
It has been shown in many settings that certain hub nodes play critical roles in biological networks. Accordingly, our ceRNA network revealed 22 nodes with a degree score exceeding 10, com indicating that they were particularly important. These hubs consisted of 3 lncRNAs and 19 miRNAs ( Table 1 ). The 3 lncRNAs (MAGI2-AS3, ADAMTS9-AS2, and LINC00330) had particularly high node degrees and were likely key nodes involved in the origin and development of BCa. As it has also been demonstrated that lncRNAs, miRNAs, and mRNAs interact and share similar coexpression patterns in ceRNA networks, linked mRNAs and miRNAs were extracted and new subnetworks for these 3 lncRNAs were constructed. 
Survival analysis
To investigate if any highlighted RNAs affected overall survival in patients with BCa, we performed Kaplan-Meier curve analysis to identify any prognostic signatures. This suggested that all of the key DElncRNAs, except LINC00330, associated with BCa progression. High expression of 6 DElncRNAs, including AC112721.1, ADAMTS9-AS1, ADAMTS9-AS2, HCG22, MYO16-AS1, and SACS-AS1, associated with poor prognoses (Fig. 11) . Similar to the overall DElncRNA assessments, survival analysis for DEmiRNA-195 showed that DEmirRNAs have negative effects on the overall survival of patients (Fig. 11 ). In addition, there were 6 DEmRNAs that significantly associated with overall survival, including CCNB1, FAM129A, MAP1B, and TMEM100. High expression of these mRNAs negatively associated with overall survival. Conversely, higher expression of AIFM3 and HOXB5 predicted greater patient survival time.
Discussion
Human bladder carcinoma is a considerable global health concern, [43] although the molecular mechanisms that contribute to BCa progression remain unclear. This presents an obstacle to the development of new tools for diagnosis, prognosis, and identifying drug targets. While, ncRNAs have been shown to play a role in tumorigenesis through "miRNA-bridges," a full understand of the interactions that lead to cancer development are uncertain. [44, 45] One tool that can be used investigate the links between ncRNAs and cancer are competing endogenous RNA (ceRNA) networks. These can be applied to establish the posttranscriptional layers of gene regulation in a system. To ascertain whether there are ncRNAs that may be involved in the progression of BCa, we systematically constructed ceRNA networks using patient BCa data and examined links to DElncRNAs. This involved integrating multilevel molecular profiles from large-scale studies found in the TCGA database. The initial ceRNA network we constructed was comprised of 23 miRNA nodes, 52 mRNA nodes, 59 lncRNA nodes, and 365 edges, suggesting numerous lncRNAs that may be involved in gene regulatory networks and BCa genesis. To establish a mechanistic underpinning of the role of lncRNAs in BCa, we used GO and pathway analysis to assess biological functions enriched among the DEmRNAs linked in the ceRNA network. This revealed 300 GO terms enriched in BCa versus normal tissue, 122 of which had P < .05 and Benjamini corrected P < .05. These significant GO terms included processes involved in the negative regulation of cell migration, regulation of cellular metabolic process, and regulation of cell proliferation, consistent with previous findings.
[ 46, 47] Pathway analysis revealed 15 pathways that were enriched in the dataset, primarily involving microRNAs in cancer, prostate cancer, and the p53 signaling. These pathways have all been shown to play important roles in BCa. [48, 49] Of the 3 RNA families examined in our study, lncRNAs are considered to have the greatest potential as diagnostic and prognostic biomarkers due to close associations between lncRNAs expression and function. [50] For example, many studies have shown that differential lncRNA expression is closely related to tumor pathogenesis and prognosis in breast cancer, gastric cancer, liver cancer, lung cancer, and kidney cancer. [51] [52] [53] [54] [55] However, the diagnostic role of lncRNAs in BCa has not been fully investigated. To establish this, our study used the newly constructed ceRNA network to identify lncRNA hub nodes that could serve as novel biomarkers for BCa clinical diagnosis and treatment. This revealed 3 lncRNAs (MAGI2-AS3, ADAMTS9-AS2, and LINC00330) as topological key nodes with node degrees higher than other lncRNAs. This strongly suggests that Table 1 Differentially expressed genes with node degree >10.
Number
Gene these key lncRNAs are involved in BCa genesis and progression, although this will require experiment validation in future studies. Nevertheless, we selected these lncRNAs for further analysis, constructing separate subnetworks centered around the individual lncRNAs.
The lncRNA MAGI2-AS3 had the highest node degree among the 3 key lncRNAs and was connected to numerous mRNAs and miRNAs that have been previously been shown to be involved in BCa, such as miR-200 and miR-143, validating our approach. Using the lncRNA MAGI2-AS3-miRNA-mRNA subnetwork [56] Further analysis of the GO and pathway analysis for connected mRNAs indicated 319 GO terms and 7 pathways enriched in the network, all of which have been shown to be involved in BCa. [57] In particular, the PI3K/AKT signaling pathway has been shown to trigger a signaling cascade that regulates cancer cell proliferation, invasion, metastasis, and survival, in addition to affecting patient prognosis. [58] [59] [60] The PI3K/AKT signaling pathway has also been implicated in BCa and down-regulation of miR-29c inhibits cell proliferation in a BCa cell line via the PI3K/AKT pathway. [61] ADAMTS9-AS2 was the second key lncRNA we identified and is an antisense overlapping lncRNA located upstream from ADAMTS9, a newly described tumor suppressor gene. [18] Yao et al examined experimental data to suggest that a decrease in lncRNA ADAMTS9-AS2 expression associated with the diagnosis, clinicopathological characteristics, and prognosis of glioma. This suggests that ADAMTS9-AS2 is involved in suppressing cell migration, partly by regulating the protein coding gene ADAMTS9. [62] Our survival analysis also indicated that ADAMTS9-AS2 was important to the progression of BCa and high expression associated with poor prognosis. Examination of the lncRNA ADAMTS9-AS2-miRNA-mRNA subnetwork created in the study indicated that ADAMTS9-AS2 regulates the expression of several BCa-related mRNAs, again through competitive interactions with various miRNAs, such as miR-200 and miR-141. Several studies have confirmed that both miR-200 and miR-141 have the potential to be used for the diagnosis of invasive bladder tumors, even after being missed through pathologic assessments of bladder biopsy specimens. [63, 64] Our analysis also revealed 277 GO terms and 8 pathways enriched in the mRNAs in the subnetwork, all previously implicated in BCa. Among these signaling pathways, the p53 signaling pathway has been shown to play a critical role in cancer pathogenesis and treatment (apoptosis) resistance. p53 is therefore an important cellular drug target [65, 66] and is also involved in the pathogenic mechanisms of BCa. For example, Zhu et al confirmed that downregulation of the tumor suppressor gene LOC572558 regulates p53 signaling in BCa. [67] The lncRNA LINC00330 that was highlighted in the study is a relatively underreported lncRNA, although examination of the LINC00330-miRNA-mRNA subnetwork suggests it may have the greatest potential for use as a diagnostic or prognostic biomarker. Our analysis suggests that LINC00330 regulates the expression of numerous BCa-related mRNAs through interactions with miRNAs involved in the regulation of tumor progression, including miR-195 and miR-145. Both miR-195 and miR-145 are well-described tumor-suppressing miRNAs that promote apoptosis and inhibit cell proliferation, tumor angiogenesis, and metastasis. [68] [69] [70] [71] [72] Our survival analysis indicated that a high expression of miR-195 correlates with worse prognoses for patients with BCa. Previous reports also suggest that the lncRNA UCA1 promotes mitochondrial function during BCa by modulating the miR-195/ARL2 signaling pathway. [73] We also examined the GO and pathway annotations for the mRNAs in the subnetwork, revealing 152 GO terms and 6 pathways that were enriched. These included numerous signaling pathways, including the Wnt signaling pathway that has been shown to regulate cell fate decisions and to affect cell proliferation, morphology, migration, apoptosis, or differentiation in a wide varieties of tissues. [74, 75] The Wnt signaling pathway has also been shown to be involved in BCa. For instance, Chen et al [76] confirmed that HBO1 promotes BCa proliferation and tumorigenicity via activation of the Wnt signaling pathway. Moreover, we noted that some of the lncRNAs were associated with overall survival in patients with BCa, specifically AC112721.1, ADAMTS9-AS1, HCG22, MYO16-AS1, and SACS-AS1. However, these key lncRNAs were novel RNAs associated with BCa, suggesting that they are seldom reported.
MRNAs, the hub elements of the ceRNA network, can be directly targeted by miRNAs or have indirect interactions with lncRNAs mediated by miRNAs. Similar to the lncRNAs and miRNAs, some mRNAs were also found to be associated with the survival of BCa patients. Examples of such are mRNA CCNB1, FAM129A, MAP1B, TMEM100, AIFM3, and HOXB5. Chai et al [77] revealed that the high-level expression of CCNB1 is closely associated with poor prognosis in hepatocellular carcinoma (HCC) patients. Taylor et al [78] suggested that low expression of FAM129A acted as predictor of poor prognosis with multiple probes, while low tissue mRNA expression of FAM129A was also associated with a poor outcome. [79] Previous studies have demonstrated that MAP1B interacts with p53 to influence mediated cell apoptosis and proliferation, and loss of this gene may contribute to the cancer cell's ability proliferate. [80] In addition, Han et al had found that TMEM100 was used as cancer suppressor in HCC and nonsmall cell lung cancer. [81] Additionally, AIFM3 has been reported to act as a direct target of miR-210 that is related to proliferation of human hepatoma cells. [82] Moreover, Luo et al have confirmed that HOXB5 was over-expressed in BCa tissues and promoted cell proliferation and the migration of BCa cells, indicating HOXB5s ability to act as an oncogene. [83] 
Conclusions
We have constructed an lncRNA-miRNA-mRNA network based on the ceRNA hypothesis. This has enabled us to conduct an overarching review and analysis of lncRNAs that associate with the development of BCa. Three key lncRNAs were identified (MAGI2-AS3, ADAMTS9-AS2, and LINC00330) that likely play important roles in the development and progression of BCa. This study contributes to understanding the pathogenesis of BCa and the role that lncRNAs play in disease progression. These novel lncRNAs may serve as candidate diagnostic biomarkers or therapeutic targets to improve future treatment options for BCa. 
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